Radioactive drug could shrink aggressive prostate tumors before surgery
NCT ID NCT06798558
First seen Feb 23, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests a radioactive drug (Lu-177-PSMA-617) given before surgery to men with high-risk prostate cancer. The goal is to see if the drug can shrink or eliminate the tumor, making surgery more effective. About 54 men with aggressive prostate cancer will receive the drug and then have their prostate removed to check the results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20057, United States
Contact
-
MedStar Washington Hospital Center
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Conditions
Explore the condition pages connected to this study.